Search

Your search keyword '"Juneau, Daniel"' showing total 237 results
Start Over Author "Juneau, Daniel"
237 results on '"Juneau, Daniel"'

4. Chest Pain Evaluation: Diagnostic Testing

Author

Chow, Benjamin J.W., Galiwango, Paul, Poulin, Anthony, Raggi, Paolo, Small, Gary, Juneau, Daniel, Kazmi, Mustapha, Ayach, Bilal, Beanlands, Rob S., Sanfilippo, Anthony J., Chow, Chi-Ming, Paterson, D. Ian, Chetrit, Michael, Jassal, Davinder S., Connelly, Kim, Larose, Eric, Bishop, Helen, Kass, Malek, Anderson, Todd J., Haddad, Haissam, Mancini, John, Doucet, Katie, Daigle, Jean-Sebastien, Ahmadi, Amir, Leipsic, Jonathan, Lim, Siok Ping, McRae, Andrew, and Chou, Annie Y.

Published
2023
Full Text
View/download PDF

10. Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.

Author

Pouliot, Frédéric, Saad, Fred, Rousseau, Etienne, Richard, Patrick O., Zamanian, Atefeh, Probst, Stephan, Lévesque, Éric, Castonguay, Vincent, Marcoux, Nicolas, Lodde, Michele, Juneau, Daniel, Hamilou, Zineb, Lattouf, Jean-Baptiste, Buteau, François-Alexandre, Pavic, Michel, Castilloux, Jean-François, Neveu, Bertrand, Bouvet, Guillaume F., Allard, Catherine, and Tétu, Amélie

Published
2024
Full Text
View/download PDF

20. SPECT/CT to quantify early small airway disease and its relationship to clinical symptoms in smokers with normal lung function: a pilot study.

Author

Juneau, Daniel, Leblond, Antoine, Chatta, Rami, Lévesque, Valérie, Lussier, Annabelle, and Dubé, Bruno-Pierre

Subjects
SINGLE-photon emission computed tomography, FORCED expiratory volume, PULMONARY function tests, KIRKENDALL effect, VITAL capacity (Respiration)
Abstract

Introduction: Smokers frequently display respiratory symptoms despite the fact that their pulmonary function tests (PFTs) can be normal. Quantitative lung ventilation single-photon emission computed tomography (SPECT/CT) can provide a quantification of lung ventilatory homogeneity and could prove useful as an early marker of airway disease in smokers. We measured the effects of smoking on regional ventilation distribution in subjects with normal lung function and evaluated whether ventilation distribution in these subjects is related to lung function tests results and clinical symptoms. Methods: Subjects without any history of respiratory disease were prospectively recruited and separated in two groups: active smokers (AS: =10 cigarettes/day and history of =15 pack-years) and never smokers (NS: lifetime exposure of <5 cigarettes). All subjects performed PFTs (which had to be normal, defined as zscore values of forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, total lung capacity (TLC) residual volume and diffusion capacity (DLCO) all falling between -1.65 and +1.65) and underwent SPECT/CT with Technegas, which generated subject-specific ventilation heterogeneity maps. The area under the compensated coefficient of variation (CV) density curve for CV values > 40%, (AUC-CV40%) was used as the measure of ventilation heterogeneity. Results: 30 subjects were recruited (15 per group). Subjects in the AS group displayed higher dyspnea levels (1 [1-2] vs. 0 [0-1] units on mMRC scale, p < 0.001). AUC-CV40% was significantly higher in the AS group (0.386 ± 0.106 vs. 0.293 ± 0.069, p = 0.004). AUC-CV40% was significantly correlated to FEV1 (rho = -0.47, p = 0.009), DLCO (rho = -0.49, p = 0.006), CAT score (rho = 0.55, p = 0.002) and mMRC score (rho = 0.54, p = 0.002). Subjects with mMRC >0 had higher AUC-CV40% values than those without dyspnea (0.289 ± 0.071 vs. 0.378 ± 0.102, p = 0.006), while FEV1 and DLCO were not different between those groups. ROC analyses showed that the AUC for AUC-CV40% in identifying subjects with mMRC score >0 was 0.78 (95%CI 0.61-0.95, p = 0.009), which was significantly higher than that of FEV1 and DLCO. Discussion: In smokers with normal lung function, ventilatory inhomogeneities can be quantified using SPECT/CT. AUC-CV40% values are related to lung function decline and to respiratory symptomatology, suggesting a potential role for this marker in the evaluation of symptomatic smokers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Author

Pouliot, Frederic, Saad, Fred, Rousseau, Étienne, Richard, Patrick O., Zamanian, Atefeh, Probst, Stephan, Levesque, Eric, Castonguay, Vincent, Marcoux, Nicolas, Juneau, Daniel, Lodde, Michele, Lattouf, Jean-Baptiste, Buteau, François-Alexandre, Hamilou, Zineb, Pavic, Michel, Castilloux, Jean-François, Bouvet, Guillaume, Tetu, Amélie, Guérin, Brigitte, and Beauregard, Jean-Mathieu

Published
2024
Full Text
View/download PDF

38. [18F]Fluoropyridine‐losartan: A new approach toward human Positron Emission Tomography imaging of Angiotensin II Type 1 receptors

Author

Abreu Diaz, Aida Mary, primary, Rodriguez Riera, Zalua, additional, Lee, Yanick, additional, Esteves, Luis Miguel, additional, Normandeau, Charles‐Olivier, additional, Fezas, Baptiste, additional, Hernandez Saiz, Alejandro, additional, Tournoux, François, additional, Juneau, Daniel, additional, and DaSilva, Jean N., additional

Published
2023
Full Text
View/download PDF

39. Screening Tools for the Detection of Clinically Silent and Potentially Clinically Important Cardiac Sarcoidosis

Author

De Bortoli, Alessandro, primary, Dawson, Kristin A., additional, Hashem, Dalia, additional, Spence, Stewart David, additional, Pena, Elena, additional, Inacio, João R., additional, Nery, Pablo B., additional, Juneau, Daniel, additional, Dwivedi, Girish, additional, Beanlands, Rob SB, additional, Paterson, David Ian, additional, and Birnie, David, additional

Published
2023
Full Text
View/download PDF

40. PSMA-PET/CT guided intensification of radiotherapy for prostate cancer (PSMAgRT): Findings of detection rate, impact on cancer management, and early toxicity from a phase 2 randomised controlled trial

Author

Petit, Claire, primary, Delouya, Guila, additional, Taussky, Daniel, additional, Barkati, Maroie, additional, Lambert, Carole, additional, Beauchemin, Marie-Claude, additional, Clavel, Sebastien, additional, Mok, Gary, additional, Paré, Anne-Sophie Gauthier, additional, Nguyen, Thu-van, additional, Duplan, Danny, additional, Visith Keu, Khun, additional, Saad, Fred, additional, Juneau, Daniel, additional, and Ménard, Cynthia, additional

Published
2023
Full Text
View/download PDF

43. 46: PSMA-PET/CT Guided Intensification of Radiotherapy for Prostate Cancer (PSMAGRT): Findings of Detection Rate, Impact on Cancer Management, and Early Toxicity from a Phase 2 Randomized Controlled Trial

Author

Petit, Claire, primary, Delouya, Guila, additional, Taussky, Daniel, additional, Barkati, Maroie, additional, Lambert, Carole, additional, Beauchemin, Marie-Claude, additional, Clavel, Sébastien, additional, Mok, Gary, additional, Paré, Anne-Sophie Gauthier, additional, Nguyen, Thu-van, additional, Duplan, Danny, additional, Keu, Khun Visith, additional, Saad, Fred, additional, Juneau, Daniel, additional, and Ménard, Cynthia, additional

Published
2022
Full Text
View/download PDF

44. 174: Influence of Palliative Radiotherapy on Toxicity and Survival in Patients Treated with Radium-223 Dichloride for Metastatic Castrate-Resistant Prostate Cancer

Author

Charrois-Durand, Cédric, primary, Delouya, Guila, additional, Taussky, Daniel, additional, Barkati, Maroie, additional, Saad, Fred, additional, Lattouf, Jean-Baptiste, additional, Perrotte, Paul, additional, Karakiewicz, Pierre, additional, Soulières, Denis, additional, Blais, Normand, additional, Hamilou, Zineb, additional, Juneau, Daniel, additional, and Plouznikoff, Nicolas, additional

Published
2022
Full Text
View/download PDF

45. A Reliable Production System of Large Quantities of [ 13 N]Ammonia for Multiple Human Injections.

Author

Alonso Martinez, Luis Michel, Naim, Nabil, Saiz, Alejandro Hernandez, Simard, José-Mathieu, Boudjemeline, Mehdi, Juneau, Daniel, and DaSilva, Jean N.

Subjects
RADIOACTIVE tracers, CURRENT good manufacturing practices, AMMONIA, POSITRON emission tomography
Abstract

[13N]Ammonia is one of the most commonly used Positron Emission Tomography (PET) radiotracers in humans to assess myocardial perfusion and measure myocardial blood flow. Here, we report a reliable semi-automated process to manufacture large quantities of [13N]ammonia in high purity by proton-irradiation of a 10 mM aqueous ethanol solution using an in-target process under aseptic conditions. Our simplified production system is based on two syringe driver units and an in-line anion-exchange purification for up to three consecutive productions of ~30 GBq (~800 mCi) (radiochemical yield = 69 ± 3% n.d.c) per day. The total manufacturing time, including purification, sterile filtration, reformulation, and quality control (QC) analyses performed before batch release, is approximately 11 min from the End of Bombardment (EOB). The drug product complies with FDA/USP specifications and is supplied in a multidose vial allowing for two doses per patient, two patients per batch (4 doses/batch) on two separate PET scanners simultaneously. After four years of use, this production system has proved to be easy to operate and maintain at low costs. Over the last four years, more than 1000 patients have been imaged using this simplified procedure, demonstrating its reliability for the routine production of large quantities of current Good Manufacturing Practices (cGMP)-compliant [13N]ammonia for human use. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer

Author

Charrois-Durand, Cédric, Saad, Fred, Barkati, Maroie, Lattouf, Jean-Baptiste, Perrotte, Paul, Karakiewicz, Pierre I., Soulières, Denis, Blais, Normand, Hamilou, Zineb, Juneau, Daniel, Plouznikoff, Nicolas, Taussky, Daniel, and Delouya, Guila

Subjects
Urology, Original Research
Abstract

Introduction: We aimed to investigate several clinical and biochemical parameters, including palliative external beam radiation therapy (EBRT) to predict survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Methods: We tested known and possible prognostic parameters, including palliative EBRT, both prior and concurrent to 223Ra. Log-rank test (Kaplan-Meier method) and Cox regression analysis were used to predict overall survival (OS). Results: A total of 133 patients were treated with 223Ra; median age was 72 years. Median OS was 9.0 (95% confidence interval [CI] 7.4–10.6) months. By univariate analysis (log-rank test), baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 (p=0.001), ≥5 cycles of 223Ra (p

Published
2022
Full Text
View/download PDF

48. [18F]Fluoropyridine‐losartan: A new approach toward human Positron Emission Tomography imaging of Angiotensin II Type 1 receptors.

Author

Abreu Diaz, Aida Mary, Rodriguez Riera, Zalua, Lee, Yanick, Esteves, Luis Miguel, Normandeau, Charles‐Olivier, Fezas, Baptiste, Hernandez Saiz, Alejandro, Tournoux, François, Juneau, Daniel, and DaSilva, Jean N.

Subjects
POSITRON emission tomography, ANGIOTENSIN II, COPPER, QUALITY control, RADIOLYSIS, LOSARTAN, CLICK chemistry
Abstract

Angiotensin II type 1 receptors (AT1R) blocker losartan is used in patients with renal and cardiovascular diseases. [18F]fluoropyridine‐losartan has shown favorable binding profile for quantitative renal PET imaging of AT1R with selective binding in rats and pigs, low interference of radiometabolites and appropriate dosimetry for clinical translation. A new approach was developed to produce [18F]fluoropyridine‐losartan in very high molar activity. Automated radiosynthesis was performed in a three‐step, two‐pot, and two‐HPLC‐purification procedure within 2 h. Pure [18F]FPyKYNE was obtained by radiofluorination of NO2PyKYNE and silica‐gel‐HPLC purification (40 ± 9%), preventing the formation of nitropyridine‐losartan in the second step. Conjugation with trityl‐losartan azide via click chemistry, followed by acid hydrolysis, C18‐HPLC purification and reformulation provided [18F]fluoropyridine‐losartan in 11 ± 2% (decay‐corrected from [18F]fluoride, EOB). Using tris[(1‐(3‐hydroxypropyl)‐1H‐1,2,3‐triazol‐4‐yl)methyl]‐amine (THPTA) as a Cu(I)‐stabilizing agent for coupling [18F]FPyKYNE to the unprotected losartan azide afforded [18F]fluoropyridine‐losartan in similar yields (11 ± 3%, decay‐corrected from [18F]fluoride, EOB). Reverse‐phase HPLC was optimized by reducing the pH of the mobile phase to achieve complete purification and high molar activities (467 ± 60 GBq/μmol). The use of radioprotectants prevented tracer radiolysis for 10 h (RCP > 99%). The product passed the quality control testing. This reproducible automated radiosynthesis process will allow in vivo PET imaging of AT1R expression in several diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results